Evidence map›Paper›PMID 30090086›Full record

ReviewFrontiers in endocrinology2018

3,5-Diiodothyronine: A Novel Thyroid Hormone Metabolite and Potent Modulator of Energy Metabolism.

Rosalba Senese, Pieter de Lange, Giuseppe Petito, Maria Moreno, Fernando Goglia, Antonia Lanni

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. Thyroid Hormone Effects on Glucose Disposal in Patients With Insulin Receptor Mutations.The Journal of clinical endocrinology and metabolism · 2020
    Trial
  2. Review
  3. Article
  4. Article
  5. Thyroid hormones, mitochondria, aging, and cancer.Frontiers in endocrinology · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Cryo-EM: A new dawn in thyroid biology.Molecular and cellular endocrinology · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rosalba SeneseDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "L. Vanvitelli" , Caserta, Italy.
Pieter de LangeDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "L. Vanvitelli" , Caserta, Italy.
Giuseppe PetitoDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "L. Vanvitelli" , Caserta, Italy.
Maria MorenoDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
Fernando GogliaDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
Antonia LanniDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "L. Vanvitelli" , Caserta, Italy.
University of Campania "Luigi Vanvitelli" · ITUniversity of Sannio · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 30 years of research has demonstrated that 3,5-diiodo-L-thyronine (3,5-T2), an endogenous metabolite of thyroid hormones, exhibits interesting metabolic activities. In rodent models, exogenously administered 3,5-T2 rapidly increases resting metabolic rate and elicits short-term beneficial hypolipidemic effects; however, very few studies have evaluated the effects of endogenous and exogenous T2 in humans. Further analyses on larger cohorts are needed to determine whether 3,5-T2 is a potent additional modulator of energy metabolism. In addition, while several lines of evidence suggest that 3,5-T2 mainly acts through Thyroid hormone receptors (THRs)- independent ways, with mitochondria as a likely cellular target, THRs-mediated actions have also been described. The detailed cellular and molecular mechanisms through which 3,5-T2 elicits a multiplicity of actions remains unknown. Here, we provide an overview of the most recent literature on 3,5-T2 bioactivity with a particular focus on short-term and long-term effects, describing data obtained through

Indexed as

energy balancefatty acids oxidationinsulin resistance (IR)mitochondriaobesitythyroid hormones

Identifiers

PMID30090086
PMCPMC6068267
OpenAlexW2884437170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.